Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib

Journal of Thoracic Oncology

Volumn 9, Issue 12, 2014, Pages 1821-1825

  Ou, Sai Hong Ignatius ^a   Klempner, Samuel J ^a   Greenbowe, Joel R ^b   Azada, Michele ^a   Schrock, Alexa B ^b   Ali, Siraj M ^b   Ross, Jeffrey S ^b,c   Stephens, Philip J ^b   Miller, Vincent A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FOUNDATION MEDICINE   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

Alectinib resistance; Alk i1171n; Alk i1171s; Alk rearranged nsclc; HIP1 ALK; Hydrophobic regulatory spine; Next generation sequencing

Indexed keywords

ALECTINIB; AMINO ACID; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; CARBAZOLE DERIVATIVE; DNA BINDING PROTEIN; HIP1 PROTEIN, HUMAN; ONCOPROTEIN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CASE REPORT; DRUG DOSE REDUCTION; EML4 ALK GENE; FEMALE; FUSION GENE; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC VARIABILITY; HEADACHE; HIP1 ALK FUSION GENE; HIP1 GENE; HUMAN; HYDROPHOBICITY; LIVER METASTASIS; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY;

ADULT; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84925687730     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000368     Document Type: Article

References (15)

1. Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32:5 s (suppl; abstr 8002).
2. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
3. Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17:1351-1375.
4. Fang DD, Zhang B, Gu Q, et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol 2014;9:285-294.
5. Hong M, Kim RN, Song JY, et al. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. J Thorac Oncol 2014;9:419-422.
6. Ou SH, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014;9:549-553.
7. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t (5;7) (q33;q11.2). Blood 1998;91:4419-4426.
8. Nextprot BETA, HIP1 Entry. Available at: http://www.nextprot.org/db/entry/NX-O00291/structures. Accessed July 14, 2014.
9. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-935.
10. Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011;78:999-1005.
11. Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res 2013;11:122-132.
12. Zdzalik D, Dymek B, Grygielewicz P, et al. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. J Cancer Res Clin Oncol 2014;140:589-598.
13. Kornev AP, Haste NM, Taylor SS, Eyck LF. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 2006;103:17783-17788.
14. Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014;351:215-221.
15. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-673.